title: The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.
abstract: BACKGROUND
  Men with a BRCA2 mutation face an increased risk of prostate cancer. These cancers tend to have an aggressive nature and it has not yet been demonstrated that regular screening of BRCA2 carriers is associated with improved survival.
  
  
  METHODS
  We identified 4187 men who underwent a prostate cancer biopsy for an elevated PSA or an abnormal digital rectal examination between 1998 and 2010. We screened the BRCA2 gene in its entirety for mutations and we followed the men for death from prostate cancer until December 2012.
  
  
  RESULTS
  The 12-year prostate cancer-specific survival rate was 94.3% for men without a BRCA2 mutation and was 61.8% for men with a mutation (P<10(-4); log-rank test).
  
  
  CONCLUSIONS
  The survival of men with screen-detected prostate cancer and a BRCA2 mutation is much poorer than expected.
authors.affiliation: 1] Women's College Research Institute, Women's College Hospital, 790 Bay St, Toronto, ON M5G 1N8, USA [2] Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Akbari
authors.affiliation: 1] Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA [2] Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA.
authors.forename: C J D
authors.initials: CJ
authors.lastname: Wallis
authors.affiliation: Division of Radiology, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA.
authors.forename: A
authors.initials: A
authors.lastname: Toi
authors.affiliation: 1] Division of Urology, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA [2] Princess Margaret Hospital, 610 University Ave, Toronto, ON M5T 2M9, USA.
authors.forename: J
authors.initials: J
authors.lastname: Trachtenberg
authors.affiliation: Women's College Research Institute, Women's College Hospital, 790 Bay St, Toronto, ON M5G 1N8, USA.
authors.forename: P
authors.initials: P
authors.lastname: Sun
authors.affiliation: 1] Women's College Research Institute, Women's College Hospital, 790 Bay St, Toronto, ON M5G 1N8, USA [2] Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Narod
authors.affiliation: 1] Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA [2] Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Nam
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D024682:BRCA2 Protein / Q000235:genetics*; D001706:Biopsy; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D051517:Digital Rectal Examination; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D060787:Neoplasm Grading; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality*; D015996:Survival Rate
chemical_list: D024682:BRCA2 Protein; D017430:Prostate-Specific Antigen
references.citation: J Clin Oncol. 2013 May 10;31(14):1748-57
references.pmid: 23569316
references.citation: N Engl J Med. 2009 Mar 26;360(13):1310-9
references.pmid: 19297565
references.citation: Eur Urol. 2014 Sep;66(3):489-99
references.pmid: 24484606
references.citation: Br J Cancer. 2008 Jan 29;98(2):502-7
references.pmid: 18182994
references.citation: J Natl Cancer Inst. 2007 Jun 20;99(12):929-35
references.pmid: 17565157
references.citation: J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6
references.pmid: 10433620
references.citation: J Med Genet. 2005 Sep;42(9):711-9
references.pmid: 16141007
references.citation: Br J Cancer. 2008 Jul 22;99(2):371-4
references.pmid: 18577985